Abstract
Transcriptome-based molecular subtype classification of muscle-invasive urothelial bladder cancer was shown to have prognostic and therapy-predictive relevance and thus may help to inform therapeutic decision-making. However, current classification systems rely on whole transcriptome analysis, which is expensive, requires higher amounts of tissue samples, and therefore is not compatible with the daily clinical routine. Therefore, we developed a simple and robust gene panel-based classifier method to reproduce various relevant molecular classification systems (TCGA, MDA, GSC, LundTax, and Consensus). This approach was then tested on institutional cohorts of frozen and formalin-fixed and paraffin-embedded tissue samples using reverse transcription quantitative PCR and NanoString analyses. Here, we provide a step-by-step description of our panel-based subtype classifier method.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Damrauer JS, Hoadley KA, Chism DD et al (2014) Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci 111:3110–3115
Choi W, Porten S, Kim S et al (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152–165
Robertson AG, Kim J, Al-ahmadie H et al (2017) Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171:540–556.e25
Sjödahl G, Lauss M, Lövgren K et al (2012) A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 18:3377–3368
Kamoun A, de Reyniès A, Allory Y et al (2020) A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol 77:420–433
Seiler R, Douglas J, Van Kessel KE et al (2017) Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol 72:544–554
Taber A, Christensen E, Lamy P et al (2020) Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat Commun 11:1–15
Sjödahl G, Abrahamsson J, Holmsten K et al (2021) Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur Urol S0302-2838(21):02138–02132
Kim J, Kwiatkowski D, McConkey DJ et al (2019) The cancer genome atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability. Eur Urol 75:961–964
Sjödahl G, Eriksson P, Liedberg F, Höglund M (2017) Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J Pathol 242:113–125
Marzouka NAD, Eriksson P, Rovira C et al (2018) A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci Rep 8:1–12
Olah C, Hahnen C, Nagy N et al (2021) A qPCR -based method for molecular subtype classification of urinary bladder cancer – stromal gene expressions show higher prognostic values than intrinsic tumor genes. Int J Cancer 150:856–867
Olah C, Reis H, Hoffmann MJ et al (2022) Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer. Cancer Med 12:5222–5232
Grivas P, Bismar TA, Alva AS et al (2019) Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. Urol Oncol Semin Orig Investig 38:262–268
Da Costa JB, Gibb EA, Bivalacqua TJ et al (2019) Molecular characterization of neuroendocrine-like bladder cancer. Clin Cancer Res 25:3908–3920
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Olah, C., Szarvas, T. (2023). A Panel-Based Method for the Reproduction of Distinct Molecular Subtype Classifications of Muscle-Invasive Urothelial Bladder Cancer. In: Hoffmann, M.J., Gaisa, N.T., Nawroth, R., Ecke, T.H. (eds) Urothelial Carcinoma. Methods in Molecular Biology, vol 2684. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3291-8_2
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3291-8_2
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3290-1
Online ISBN: 978-1-0716-3291-8
eBook Packages: Springer Protocols